BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial

INTRODUCTION: The safety of BCG revaccination is uncertain and there is no data on its use in patients with COVID-19. METHODS: COVID-19 convalescent adults confirmed by SARS-CoV-2 RT-PCR in South-America were 1:1 randomized in the first 14 days of symptoms to BCG intradermal vaccine or placebo and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionato, Franciele A.V., Jalalizadeh, Mehrsa, Buosi, Keini, Visacri, Marília B., Dal Col, Luciana S.B., Giacomelli, Cristiane F., Leme, Patricia A.F., Maia, Cristiane L., Moriel, Patricia, Reis, Leonardo O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212358/
https://www.ncbi.nlm.nih.gov/pubmed/35738969
http://dx.doi.org/10.1016/j.vaccine.2022.06.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212358/
https://www.ncbi.nlm.nih.gov/pubmed/35738969
http://dx.doi.org/10.1016/j.vaccine.2022.06.039

Ejemplares similares